We are building a stronger Business Community in Flemingsberg

We are actively collaborating with key stakeholders to strengthen the innovation ecosystem and promote entrepreneurship in Flemingsberg. A central part of our efforts involves being present alongside other important actors and creating meeting spaces to build close relationships with those who work in the area on a daily basis. We believe that exciting and new opportunities emerge when people come together and exchange ideas.

As part of our Business Community, we recently had the pleasure of inviting Business Sweden to present their latest report, “THE ROAD TO PERSONALISED MEDICINE.” The report highlights the transition to digital health and precision medicine across various markets and emphasizes the business opportunities this development could offer Swedish healthcare companies in Europe. See the interview below with Louise Bengtsson, Senior Consultant at Business Sweden.

Stay updated and sign up for upcoming community events here.

Portabel Health: Crowned Winner of Flemingsberg Science STARTUP Award 2025

Quickly finding the right personnel is one of the healthcare sector’s major challenges, especially in times of staff shortages and increasing demands for efficiency. Portabel Health offers a modern solution to these problems through a digital platform that makes it easy for care providers to access qualified nurses and healthcare professionals.

Press Start: The Game Hub in Flemingsberg – Finally!

On April 24th, after just two months of hard work, it was finally time for the kick-off for the game cluster Press Start. The initiative is led by Drivhuset, in close collaboration with Flemingsberg Science Foundation and Södertörn University's Innovation Station.

AlzeCure Pharma – a hope in the fight against Alzheimer’s

Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.

Go to Top